



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: October 10, 2008

To: Primary Clinical Research Associates

From: Janis Wobschall
Research Protocol Specialist

Re: N0779, Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib
PS-341) in Patients with Recurrent Glioblastoma Multiforme

A typographical error has been corrected on page 4 under the Last Registration Check criteria of the Registration Eligibility Checklist as follows:

Patient has agreed to be enrolled on ~~97~~ **94-72-52**

Please replace your current version of the checklist with this revised version. If you have any questions, please feel free to contact me.

Enclosure